Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radiation dose estimates for a new myocardial perfusion agent: (E-1-(/sup 123/I)Iodo-1-Penten-5-yl)triphenylphosphonium iodide

Conference · · J. Nucl. Med.; (United States)
OSTI ID:6611153
Phosphonium cations labeled with gamma-emitting radionuclides have been suggested as myocardial perfusion agents, since these cations penetrate the hydrophobic core of the myocardial cell membrane. A model agent, (E-I-Iodo-I-Penten-5-y1) triphenylphosphonium iodide labeled with /sup 123/I in the 1 position, shows rapid myocardial extraction and high heart:blood and heart:liver ratios in female Fischer rats. Detailed distribution studies were performed for the purpose of extrapolating radiation dose estimates for humans. Myocardial uptake in humans, estimated from rat data, would be about 4.5% of the injected activity and would have a biological half-time of 52 hours. The doses to the heart and total body would be 0.027 mGy/MBq (0.10 rad/mCi) and 0.011 mGy/MBq (0.041 rad/mCi), respectively. The doses to the kidneys and thyroid would be 0.027 mGy/MBq (0.10 rad/mCi) and 0.37 mGy/MBq (1.4 rad/mCi), respectively. The doses to other organs, including the ovaries, would not exceed 0.012 mGy/MBq (0.043 rad/mCi). These estimates indicate that the radiation doses for this new agent are within acceptable limits for human use.
Research Organization:
Oak Ridge Associated Universities (ORAU), Oak Ridge, TN
DOE Contract Number:
AC05-76OR00033
OSTI ID:
6611153
Report Number(s):
CONF-840619-
Conference Information:
Journal Name: J. Nucl. Med.; (United States) Journal Volume: 25:5
Country of Publication:
United States
Language:
English